Entresto's cost-effectiveness is supported by its demonstrated ability to reduce hospitalizations and cardiovascular events, which can lead to significant healthcare savings. Studies indicate that the drug's use is associated with lower overall healthcare costs due to fewer medical interventions and emergency room visits [1][2].
What medical conditions does Entresto treat?
Entresto, an angiotensin receptor-neprilysin inhibitor, is prescribed to treat symptomatic chronic heart failure with reduced ejection fraction in adult patients [1][3].
How does Entresto work to improve heart failure outcomes?
Entresto works by enhancing the body's natural protective systems while suppressing harmful ones. It targets the renin-angiotensin-aldosterone system (RAAS) and the natriuretic peptide system. By inhibiting neprilysin, it increases the levels of natriuretic peptides, which help to relax blood vessels, reduce sodium and water retention, and lower blood pressure. Simultaneously, it blocks the angiotensin II receptor, which helps to reduce vasoconstriction and aldosterone release [1][3].
What are the documented benefits of taking Entresto?
Clinical trials have shown that Entresto significantly reduces the risk of cardiovascular death and hospitalization for heart failure compared to enalapril, a commonly prescribed ACE inhibitor [1][3]. Patients treated with Entresto experience a lower incidence of cardiovascular mortality and a reduced rate of all-cause mortality [1][3].
How does Entresto's effectiveness compare to older heart failure medications?
In clinical studies, Entresto demonstrated superior outcomes compared to enalapril, including a greater reduction in cardiovascular death and heart failure hospitalizations [1][3]. This suggests a potential advantage over traditional ACE inhibitors and angiotensin receptor blockers in managing heart failure with reduced ejection fraction [1][3].
When did Entresto receive FDA approval?
Entresto received U.S. Food and Drug Administration (FDA) approval in July 2015 [4].
What is the typical price range for Entresto?
The cost of Entresto can vary based on insurance coverage, pharmacy, and dosage. However, without insurance, a 30-day supply can range from approximately $500 to $600 [5]. Patient assistance programs and discount cards may be available to help reduce out-of-pocket expenses [5].
Are there any generic versions of Entresto available?
As of late 2023, there are no generic versions of Entresto (sacubitril/valsartan) available in the United States [6].
How long is Entresto protected by patents?
Information regarding specific patent expiry dates for Entresto can be found on resources like DrugPatentWatch.com [7]. Pharmaceutical patents are complex and can involve multiple patents covering different aspects of the drug, including its composition, manufacturing process, and methods of use [7].
What are the potential side effects associated with Entresto?
Common side effects of Entresto include dizziness, lightheadedness, cough, fatigue, and kidney problems [3][8]. More serious potential side effects include angioedema, a severe allergic reaction that causes swelling of the face, lips, tongue, or throat, which requires immediate medical attention [3][8]. Patients with a history of angioedema related to ACE inhibitors or ARBs should not take Entresto [3][8].
Who manufactures Entresto?
Entresto is manufactured by Novartis [3].
Are there alternative treatments for heart failure with reduced ejection fraction?
Yes, alternative treatments for heart failure with reduced ejection fraction include ACE inhibitors (e.g., enalapril, lisinopril), angiotensin receptor blockers (ARBs) (e.g., valsartan, losartan), beta-blockers (e.g., carvedilol, metoprolol succinate), mineralocorticoid receptor antagonists (MRAs) (e.g., spironolactone, eplerenone), and SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) [1][3]. The choice of treatment depends on individual patient factors and clinical guidelines.
Sources:
1. https://www.drugpatentwatch.com/entresto-patent-information
2. https://www.drugpatentwatch.com/entresto-price-history
3. https://www.novartis.com/us/our-products/entresto
4. https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/entresto-sacubitril-and-valsartan-information
5. https://www.goodrx.com/entresto
6. https://www.drugpatentwatch.com/blog/entresto-generic-status
7. https://www.drugpatentwatch.com/
8. https://www.mayoclinic.org/drugs-supplements/sacubitril-and-valsartan-oral-route/side-effects/drh-20066757